Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health to Supply Belgium's First Psilocybin Compassionate Use Program, to Help Open the Door to Patient Access for Treatment-Resistant Depression

Rhelion signs Belgian supply deal for psilocybin, pending regulatory approval.

What the company is saying

Rhelion Life Sciences Corp. (CSE:RHEL, FSE:4YX0, OTCQB:TRUFF) is announcing that its subsidiary, Filament Health Corp., has entered a supply and licensing agreement with Epsylon ASBL to provide PEX010, a botanical psilocybin drug candidate, for a compassionate use program in Belgium targeting treatment-resistant depression. The company frames this as a potential first for Belgian patient access to psilocybin outside clinical trials, emphasizing regulatory support and the program’s alignment with evolving European attitudes toward psychedelic therapies. The announcement highlights support from the Psychedelic Society Belgium, which contributed expertise but has no financial or commercial ties to Rhelion or Filament. CEO Todd Shapiro positions the deal as evidence of growing European acceptance and hopes it will influence regulators. The company stresses its global reach, noting PEX010 supports over 80 research studies and is available in standardized doses of 1, 5, and 25 mg, with a 0.5 mg dose in development. Rhelion also references its April 30, 2026 acquisition of Filament, including 78 issued patents across 13 families, to underscore its intellectual property position.

What the data suggests

The agreement with Epsylon ASBL is real and specific, but actual patient access to PEX010 in Belgium is contingent on regulatory approval from the Federal Agency for Medicines and Health Products, with no approval date or timeline disclosed. PEX010 is described as a standardized, GMP-manufactured botanical psilocybin available in 1, 5, and 25 mg doses, with a 0.5 mg dose planned. Filament supports more than 80 academic and philanthropic studies worldwide with this product, indicating broad research engagement but not direct commercial revenue. The company’s intellectual property portfolio is quantified at 78 issued patents across 13 families. The announcement confirms Rhelion’s completed acquisition of Filament Health Corp. on April 30, 2026. There are no disclosed financial metrics, revenue figures, or patient enrollment numbers. The main operational milestone—regulatory approval for the Belgian program—remains pending.

Analysis

The announcement is upbeat, highlighting a new supply and licensing agreement for PEX010 in Belgium and referencing Rhelion's recent acquisition of Filament Health Corp. The realized facts include the completion of the acquisition, the existence of the supply agreement, and the size of the patent portfolio. However, the most material benefit—the actual patient access to psilocybin treatment—remains contingent on regulatory approval, with no timeline disclosed. Several claims are forward-looking, such as the expectation that the program will provide access 'once approved' and aspirations for broader regulatory change. The capital intensity flag is triggered by the acquisition of Filament and the large patent portfolio, but there is no immediate earnings impact or financial data disclosed. The gap between narrative and evidence is moderate: while the agreement is real, the main clinical and commercial benefits are not yet realized, and the language about regulatory progress and patient impact is aspirational.

Risk flags

• ●Regulatory approval is not yet secured for the Belgian compassionate use program, so the agreement’s value is entirely contingent on a positive decision by the Federal Agency for Medicines and Health Products. Without approval, no patients will receive PEX010 and no revenue or clinical data will result.
• ●There is no disclosure of financial terms, expected patient numbers, or commercial impact from this agreement, making it impossible to assess near-term revenue potential or profitability from this initiative.
• ●The announcement relies on the broader trend of increasing European openness to psychedelic therapies, but this is aspirational and not a guarantee of future regulatory or commercial success.
• ●Filament is not responsible for the conduct of the program, which is led and managed by Epsylon ASBL. This limits Rhelion’s operational control and introduces counterparty execution risk.
• ●The company highlights its intellectual property portfolio and global research support, but these do not directly translate to commercial outcomes or regulatory approvals in Belgium or other markets.

Bottom line

Rhelion’s agreement to supply PEX010 for a Belgian compassionate use program is a concrete operational step but does not guarantee near-term revenue or patient access, as regulatory approval is still pending. The company’s messaging is optimistic, leveraging the deal to position itself as a leader in regulated natural psilocybin, but the main benefits remain forward-looking. The scale of Filament’s research engagement and patent portfolio is notable, yet the lack of financial disclosure or patient numbers leaves the commercial impact unclear. Investors should watch for updates on Belgian regulatory approval and evidence of actual patient treatment or revenue generation. The most important takeaway is that while the agreement signals progress, its value is entirely dependent on future regulatory outcomes.

Announcement summary

(CSE:RHEL) (FSE:4YX0) (OTCQB:TRUFF) Rhelion Life Sciences Corp. announced that its wholly owned subsidiary, Filament Health Corp., has entered into a supply and licensing agreement with Epsylon ASBL, a Belgian non-profit association operating psychiatric hospitals, for the supply of PEX010 to a program titled 'Compassionate Use Program with psilocybin (PEX010) for the treatment of treatment resistant depression'. The program is supported by the Psychedelic Society Belgium (PSBE), which has contributed expertise in psychedelic-assisted therapy but has no financial or commercial relationship with Rhelion or Filament. Psilocybin is currently available in Belgium only within clinical trials, but Belgian law allows a compassionate use program to provide access to medicines not yet authorized for patients with serious conditions and no satisfactory authorized treatment. Each compassionate use program must be approved by the Federal Agency for Medicines and Health Products and is tied to a specific medicinal product. This program is for PEX010, and once approved, it will give patients with treatment-resistant depression access to psilocybin treatment with Filament's drug candidate. The program is led by Dr. Daniel Souery at Epsylon, which is the applicant for the program. Filament is not responsible for the conduct of the program. Todd Shapiro, Chief Executive Officer and Director of Rhelion, stated that access to psilocybin treatment is growing across Europe and expressed hope that programs like this will demonstrate to regulators that patients with serious unmet needs can be given safe, regulated access to natural psilocybin. PEX010 is Filament Health's botanical psilocybin drug candidate and is available in standardized dosing of 1, 5, and 25 mg, with a 0.5 mg dose to follow. PEX010 is produced using Filament's proprietary and patented extraction, purification, and stabilization methods, ensuring consistent composition across every dose, study, and research site. Filament supports more than 80 academic and philanthropic research studies worldwide with PEX010. On April 30, 2026, Rhelion completed its acquisition of Filament Health Corp., including its lead drug candidate PEX010 and a portfolio of 78 issued patents across 13 patent families.

Disagree with this article?